


HeartFlow RoadMap™ Analysis | SMART-CT Study

STUDY OBJECTIVE

Measure the difference in CCTA read time using RoadMap analysis¹ compared to without RoadMap analysis for Level 2 and Level 3 readers.

PRIMARY ENDPOINT




25% faster
 read time per case with RoadMap Analysis²
 No change in AUC with and without RoadMap Analysis

Boost Efficiency for Every CCTA Read

Efficiency gains realized across both Level 2 and Level 3 readers.


Efficiency Gains with RoadMap Analysis in CCTA Read Time (per case)



Elevate Consistency with Reliable Diagnoses

Increase consistency across all readers.


Inter-reader Agreement (per vessel)



Amplify Reader Confidence

Increase confidence in CCTA read by over 24%.

Reader Confidence in CCTA Read



CASES READ BY:
Three Level 2 Readers
Three Level 3 Readers

120 CCTAs
60 CCTAs with RoadMap
60 CCTAs without RoadMap

Readers blinded to core lab-measured invasive QCA for accuracy assessment

CASE SELECTION

A total of **120 cases** were selected for this study with **60 cases which had stenosis $\leq 50\%$ per QCA**. Six readers (three cardiologists and three radiologists) from two sites each read 60 CCTAs with RoadMap Analysis and 60 CCTAs without RoadMap Analysis, blinded to QCA results. The cases included varying scanner manufacturers, races, age, image quality, and disease burden.

STUDY DESIGN



1. AI Coronary Stenosis Quantification on Coronary CT Angiography versus Quantitative Coronary Angiography, presented at SCCT 2023.
2. A Study to Measure the Ability of AI-CSQ to Support The Busy CCTA Reader: SMART-CT, presented at SCCT 2023.

Legal Disclaimer: The information provided by the HeartFlow FFR_{CT} Analysis and RoadMap Analysis is intended to be used in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional judgment. The HeartFlow FFR_{CT} and RoadMap Analysis may not be appropriate for all patients. See their respective indications for use for more information.

The HeartFlow FFR_{CT} Analysis has received FDA Clearance, is CE-Marked, and is commercially available in the United States, Europe, Japan, and Canada. The RoadMap Analysis has received FDA Clearance and is commercially available in the United States.